STAMFORD, Conn.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines ...

This study analyzes BRCA testing patterns in U.S. breast cancer patients, highlighting barriers and disparities in access to genetic testing and precision care.

EHR-enabled access has the potential to streamline ordering, accelerate clinical decisions, and drive scalable precision oncology adoption. FORT MYERS, Fla., April 23, 2026--(BUSI ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side analysts ...

Genetic testing for hereditary cancers, such as breast, colon, pancreatic, and ovarian cancer, helps at-risk individuals understand their familial risk for these diseases and make informed decisions ...

BioReference® Health LLC, an OPKO Health, Inc. company and a trusted provider of diagnostic testing in the United States, today announced the launch of BioReference DirectTM, a new digital health ...

Sauce Labs Inc., a continuous testing solutions provider, today announced the general availability of its Real Device Access API, changing how the company delivers mobile testing infrastructure and ...

SLIDELL, La.--(BUSINESS WIRE)--Care Access, a global clinical research company helping to accelerate the future of medicine, is bringing its Heart & Kidney Health Screening initiative to Slidell, La.

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today the validation and launch of a new method of ...

Imagine this: someone you love has just heard the words “you have cancer.” They are meeting with their oncologist – perhaps even me, or one of my colleagues – and come to understand that there is ...

Clinical Utility of Molecular Tumor Board Review for Identification of Possible Germline Pathogenic Variants on Tumor Next-Generation Sequencing Reports Approximately 5%-10% of patients with ...